Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ING200336: Pharmacokinetics and safety of dolutegravir/abacavir/lamivudine in pregnant women with HIV
2013-003527-11Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dolutegravir, abacavir and lamivudine in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoints: Dolutegravir pharmacokinetic parameters during pregnancy and postpartum and Maternal safety. Started Mar 2014; status: completed.
02
Drugs
dolutegravirabacavirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2013-003527-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003527-11.